Issuu on Google+

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs Published on October 2011

Report Summary Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Respiratory Society's 2011 Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by COPD specialists.

Table of Content Executive Summary Scope of Analysis & Methodology Current Treatment Practice Inhaled SABA Inhaled SAMA Inhaled LABA Inhaled LAMA Combination inhaler of ICS/LABA Phosphodiesterase-4 (PDE-4) inhibitor Oral corticosteroid Methylxanthine Antibiotics Alpha-1 antitrypsin augmentation therapy Treatment Challenges / Unmet Needs COPD Treatment Map Companies Mentioned UCB Pharma GSK Merck Dey AstraZeneca Sunovion Boehringer Ingelheim Sandoz Teva Novartis Chiesi Nycomed

Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs (From Issuu)

Page 1/3


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs

Product Formats Please select the product formats and the quantity you require. Department License--USD 2 795.00

Quantity: _____

Corporate License--USD 5 590.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs (From Issuu)

Page 2/3


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

 

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs (From Issuu)

Page 3/3


Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs